Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.
To create an account please click on this link.
If you already have an account, please log in here.
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
~ New data from in vitro, in vivo, and IND enabling studies supports LP-284’s development for MCL, an aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with immediate patient needs. ~ Lantern is anticipating filing the IND with the FDA in early 2023 and initiating a first-in-human Phase 1 trial for LP-284 in NHLs, including MCL and double hit lymphoma (DHL), by mid 2023. ~ In the US and Europe, MCL and DHL are diagnosed in approximately 9,000 patients each year and have an estimated annual market potential of $1.2 billion USD.